China challenges US in AI drug race, but rivals still reliant on each other

China is emerging as a competitor to the US in the field of AI-driven drug discovery, according to Leung Chuen-yan, a private equity investor. While both countries utilize similar AI methodologies in drug development, a truly multimodal AI model capable of integrating diverse data types globally is still lacking. US pharmaceutical companies are increasingly relying on Chinese clinical data, reflecting growing trust in its alignment with global datasets. Chinese biotech firms are also collaborating with international pharmaceutical companies to commercialize their drugs in global markets. This reliance highlights the interconnectedness of the US and China in advancing AI-driven drug discovery despite their competition.

Explore how the topics in this article connect to other news stories